{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:26:49Z","timestamp":1774016809082,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Canada Research Chair in precision medicine data analysis"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["426059"],"award-info":[{"award-number":["426059"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012651","name":"Fondation Institut de Cardiologie de Montr\u00e9al","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012651","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e9 de Montr\u00e9al Beaulieu-Saucier Chair in Pharmacogenomics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00228-024-03786-3","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:53:30Z","timestamp":1734710010000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress"],"prefix":"10.1007","volume":"81","author":[{"given":"Marc-Olivier","family":"Pilon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"St-Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Jutras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime Meloche","family":"Brouillette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Mongrain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Lagac\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Provost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis-Philippe","family":"Lemieux Perreault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essaid","family":"Oussaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Busseuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christyne","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Leclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"de Denus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"10","key":"3786_CR1","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","volume":"64","author":"Y Zopf","year":"2008","unstructured":"Zopf Y, Rabe C, Neubert A, Gassmann KG, Rascher W, Hahn EG et al (2008) Women encounter ADRs more often than do men. Eur J Clin Pharmacol 64(10):999\u20131004","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3786_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000248311","volume":"84","author":"Y Zopf","year":"2009","unstructured":"Zopf Y, Rabe C, Neubert A, Janson C, Brune K, Hahn EG et al (2009) Gender-based differences in drug prescription: relation to adverse drug reactions. Pharmacology 84(6):333\u2013339","journal-title":"Pharmacology"},{"key":"3786_CR3","first-page":"187103","volume":"2011","author":"OP Soldin","year":"2011","unstructured":"Soldin OP, Chung SH, Mattison DR (2011) Sex differences in drug disposition. J Biomed Biotechnol 2011:187103","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"3786_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1300\/J074v13n04_04","volume":"13","author":"BA Perry","year":"2001","unstructured":"Perry BA, Turner LW (2001) A prediction model for polypharmacy: are older, educated women more susceptible to an adverse drug event? J Women Aging 13(4):39\u201351","journal-title":"J Women Aging"},{"issue":"3","key":"3786_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bph.12362","volume":"171","author":"F Franconi","year":"2014","unstructured":"Franconi F, Campesi I (2014) Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol 171(3):580\u2013594","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3786_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.clpt.6100226","volume":"82","author":"JB Schwartz","year":"2007","unstructured":"Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82(1):87\u201396","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3786_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48(3):143\u2013157","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3786_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41576-018-0083-1","volume":"20","author":"EA Khramtsova","year":"2019","unstructured":"Khramtsova EA, Davis LK, Stranger BE (2019) The role of sex in the genomics of human complex traits. Nat Rev Genet 20(3):173\u2013190","journal-title":"Nat Rev Genet"},{"key":"3786_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.phrs.2017.04.027","volume":"121","author":"C Tannenbaum","year":"2017","unstructured":"Tannenbaum C, Day D (2017) Age and sex in drug development and testing for adults. Pharmacol Res 121:83\u201393","journal-title":"Pharmacol Res"},{"issue":"3","key":"3786_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jchf.2019.01.009","volume":"7","author":"SH Bots","year":"2019","unstructured":"Bots SH, Groepenhoff F, Eikendal ALM, Tannenbaum C, Rochon PA, Regitz-Zagrosek V et al (2019) Adverse drug reactions to guideline-recommended heart failure drugs in women: a systematic review of the literature. JACC Heart Fail 7(3):258\u2013266","journal-title":"JACC Heart Fail"},{"issue":"18","key":"3786_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.jacc.2018.02.070","volume":"71","author":"PE Scott","year":"2018","unstructured":"Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ et al (2018) Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol 71(18):1960\u20131969","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3786_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1586\/ecp.11.29","volume":"4","author":"A Parekh","year":"2011","unstructured":"Parekh A, Fadiran EO, Uhl K, Throckmorton DC (2011) Adverse effects in women: implications for drug development and regulatory policies. Expert Rev Clin Pharmacol 4(4):453\u2013466","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"3786_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.12307","volume":"5","author":"A Levinsson","year":"2018","unstructured":"Levinsson A, Dub\u00e9 MP, Tardif JC, de Denus S (2018) Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines. ESC Heart Fail 5(5):745\u2013754","journal-title":"ESC Heart Fail"},{"issue":"6","key":"3786_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/jhn.12272","volume":"28","author":"V Turcot","year":"2015","unstructured":"Turcot V, Brunet J, Daneault C, Tardif JC, Des Rosiers C, Lettre G (2015) Validation of fatty acid intakes estimated by a food frequency questionnaire using erythrocyte fatty acid profiling in the Montreal Heart Institute Biobank. J Hum Nutr Diet 28(6):646\u2013658","journal-title":"J Hum Nutr Diet"},{"issue":"1","key":"3786_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajhg.2016.05.007","volume":"99","author":"N Chami","year":"2016","unstructured":"Chami N, Chen MH, Slater AJ, Eicher JD, Evangelou E, Tajuddin SM et al (2016) Exome genotyping identifies pleiotropic variants associated with red blood cell traits. Am J Hum Genet 99(1):8\u201321","journal-title":"Am J Hum Genet"},{"issue":"1","key":"3786_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajhg.2016.05.005","volume":"99","author":"JD Eicher","year":"2016","unstructured":"Eicher JD, Chami N, Kacprowski T, Nomura A, Chen MH, Yanek LR et al (2016) Platelet-related variants identified by exomechip meta-analysis in 157,293 individuals. Am J Hum Genet 99(1):40\u201355","journal-title":"Am J Hum Genet"},{"issue":"4","key":"3786_CR17","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/cts.13230","volume":"15","author":"M Meloche","year":"2022","unstructured":"Meloche M, Leclair G, Jutras M, Oussa\u00efd E, Gaulin MJ, Mongrain I et al (2022) Leveraging large observational studies to discover genetic determinants of drug concentrations: a proof-of-concept study. Clin Transl Sci 15(4):1063\u20131073","journal-title":"Clin Transl Sci"},{"issue":"2","key":"3786_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/tpj.2016.4","volume":"17","author":"S de Denus","year":"2017","unstructured":"de Denus S, Rouleau JL, Mann DL, Huggins GS, Cappola TP, Shah SH et al (2017) A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. Pharmacogenomics J 17(2):192\u2013200 (Epub 20160301)","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"3786_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/tpj.2017.8","volume":"18","author":"S de Denus","year":"2018","unstructured":"de Denus S, Rouleau JL, Mann DL, Huggins GS, Pereira NL, Shah SH et al (2018) CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. Pharmacogenomics J 18(2):232\u2013237","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"3786_CR20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/cts.13230","volume":"15","author":"M Meloche","year":"2022","unstructured":"Meloche M, Leclair G, Jutras M, Oussa\u00efd E, Gaulin MJ, Mongrain I et al (2022) Leveraging large observational studies to discover genetic determinants of drug concentrations: a proof-of-concept study. Clin Transl Sci 15(4):1063\u20131073","journal-title":"Clin Transl Sci"},{"issue":"8","key":"3786_CR21","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1111\/cts.13318","volume":"15","author":"MO Pilon","year":"2022","unstructured":"Pilon MO, Leclair G, Oussa\u00efd E, St-Jean I, Jutras M, Gaulin MJ et al (2022) An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites. Clin Transl Sci 15(8):2024\u20132034","journal-title":"Clin Transl Sci"},{"issue":"5","key":"3786_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/clc.22948","volume":"41","author":"S Perreault","year":"2018","unstructured":"Perreault S, Shahabi P, C\u00f4t\u00e9 R, Dumas S, Rouleau-Mailloux \u00c9, Feroz Zada Y et al (2018) Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. Clin Cardiol 41(5):576\u2013585","journal-title":"Clin Cardiol"},{"issue":"1","key":"3786_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13219","volume":"290","author":"M Casula","year":"2021","unstructured":"Casula M, Gazzotti M, Bonaiti F, Olmastroni E, Arca M, Averna M et al (2021) Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. J Intern Med 290(1):116\u201328","journal-title":"J Intern Med"},{"issue":"4","key":"3786_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R et al (2014) Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 96(4):470\u2013476","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"3786_CR25","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1001\/archinte.1989.00390120061012","volume":"149","author":"GR Gibson","year":"1989","unstructured":"Gibson GR (1989) Enalapril-induced cough. Arch Intern Med 149(12):2701\u20132703","journal-title":"Arch Intern Med"},{"issue":"6586","key":"3786_CR26","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1136\/bmj.294.6586.1521","volume":"294","author":"DM Coulter","year":"1987","unstructured":"Coulter DM, Edwards IR (1987) Cough associated with captopril and enalapril. Br Med J (Clin Res Ed) 294(6586):1521\u20131523","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"3786_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0895-4356(94)00231-E","volume":"48","author":"LE Visser","year":"1995","unstructured":"Visser LE, Stricker BH, van der Velden J, Paes AH, Bakker A (1995) Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol 48(6):851\u2013857","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"3786_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14740338.2017.1325870","volume":"16","author":"A Lanas-Gimeno","year":"2017","unstructured":"Lanas-Gimeno A, Lanas A (2017) Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf 16(6):673\u2013685","journal-title":"Expert Opin Drug Saf"},{"issue":"40","key":"3786_CR29","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/eurheartj\/ehv161","volume":"36","author":"GM Rosano","year":"2015","unstructured":"Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H et al (2015) Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J 36(40):2677\u20132680","journal-title":"Eur Heart J"},{"issue":"9","key":"3786_CR30","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2337\/dc18-0344","volume":"41","author":"JM Dennis","year":"2018","unstructured":"Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG et al (2018) Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care 41(9):1844\u20131853","journal-title":"Diabetes Care"},{"key":"3786_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.diabres.2017.07.012","volume":"131","author":"A Kautzky-Willer","year":"2017","unstructured":"Kautzky-Willer A, Harreiter J (2017) Sex and gender differences in therapy of type 2 diabetes. Diabetes Res Clin Pract 131:230\u2013241","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"3786_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1365-2753.2009.01280.x","volume":"16","author":"V Vlckova","year":"2010","unstructured":"Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir S (2010) Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study. J Eval Clin Pract 16(6):1124\u20131128","journal-title":"J Eval Clin Pract"},{"issue":"5","key":"3786_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2165\/00002018-200932050-00004","volume":"32","author":"V Vlckova","year":"2009","unstructured":"Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA (2009) Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 32(5):409\u2013418","journal-title":"Drug Saf"},{"issue":"1","key":"3786_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2165\/00002018-199207010-00004","volume":"7","author":"RC Parish","year":"1992","unstructured":"Parish RC, Miller LJ (1992) Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update Drug Saf 7(1):14\u201331","journal-title":"An update Drug Saf"},{"issue":"6","key":"3786_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","volume":"22","author":"M Ucar","year":"2000","unstructured":"Ucar M, Mj\u00f6rndal T, Dahlqvist R (2000) HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22(6):441\u2013457","journal-title":"Drug Saf"},{"key":"3786_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.phrs.2017.01.023","volume":"119","author":"I Campesi","year":"2017","unstructured":"Campesi I, Franconi F, Seghieri G, Meloni M (2017) Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. Pharmacol Res 119:195\u2013207","journal-title":"Pharmacol Res"},{"issue":"8","key":"3786_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al (2008) SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study. N Engl J Med 359(8):789\u2013799","journal-title":"N Engl J Med"},{"issue":"3","key":"3786_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/clpt.2013.96","volume":"94","author":"CM Blake","year":"2013","unstructured":"Blake CM, Kharasch ED, Schwab M, Nagele P (2013) A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther 94(3):394\u2013399","journal-title":"Clin Pharmacol Ther"},{"key":"3786_CR39","doi-asserted-by":"crossref","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van\u2019t Hof AWJ, van der Harst P, et al (2019) A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med 381(17):1621\u201331","DOI":"10.1056\/NEJMoa1907096"},{"issue":"12","key":"3786_CR40","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jama.2017.11469","volume":"318","author":"BF Gage","year":"2017","unstructured":"Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N et al (2017) Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: The GIFT Randomized Clinical Trial. JAMA 318(12):1115\u20131124","journal-title":"JAMA"},{"issue":"13","key":"3786_CR41","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT et al (2017) Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 318(13):1250\u20131259","journal-title":"JAMA"},{"key":"3786_CR42","doi-asserted-by":"publisher","first-page":"i2868","DOI":"10.1136\/bmj.i2868","volume":"353","author":"J Jaspers Focks","year":"2016","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB et al (2016) Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 353:i2868","journal-title":"BMJ"},{"issue":"2","key":"3786_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/europace\/euu225","volume":"17","author":"JB Olesen","year":"2015","unstructured":"Olesen JB, S\u00f8rensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP et al (2015) Non-vitamin K antagonist oral anticoagulation agents in anticoagulant na\u00efve atrial fibrillation patients: Danish nationwide descriptive data 2011\u20132013. Europace 17(2):187\u2013193","journal-title":"Europace"},{"issue":"4","key":"3786_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/CIRCOUTCOMES.114.000907","volume":"8","author":"PA Patel","year":"2015","unstructured":"Patel PA, Zhao X, Fonarow GC, Lytle BL, Smith EE, Xian Y et al (2015) Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack. Circ Cardiovasc Qual Outcomes 8(4):383\u2013392","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"3786_CR45","doi-asserted-by":"publisher","first-page":"e000535","DOI":"10.1161\/JAHA.113.000535","volume":"2","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC et al (2013) Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc 2(6):e000535","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"3786_CR46","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S0735-1097(02)02379-3","volume":"40","author":"J Butler","year":"2002","unstructured":"Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA et al (2002) Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 40(9):1589\u20131595","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"3786_CR47","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.107.706820","volume":"117","author":"CA Jackevicius","year":"2008","unstructured":"Jackevicius CA, Li P, Tu JV (2008) Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117(8):1028\u20131036","journal-title":"Circulation"},{"issue":"16","key":"3786_CR48","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCULATIONAHA.108.830299","volume":"120","author":"G Mazzaglia","year":"2009","unstructured":"Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V et al (2009) Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 120(16):1598\u20131605","journal-title":"Circulation"},{"issue":"10","key":"3786_CR49","first-page":"1028","volume":"20","author":"TW Cutler","year":"2014","unstructured":"Cutler TW, Chuang A, Huynh TD, Witt RG, Branch J, Pon T et al (2014) A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manag Care Spec Pharm 20(10):1028\u20131034","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"3786_CR50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/jth.12845","volume":"13","author":"A Gorst-Rasmussen","year":"2015","unstructured":"Gorst-Rasmussen A, Skj\u00f8th F, Larsen TB, Rasmussen LH, Lip GY, Lane DA (2015) Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 13(4):495\u2013504","journal-title":"J Thromb Haemost"},{"issue":"24","key":"3786_CR51","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342\u20132352","journal-title":"N Engl J Med"},{"issue":"5","key":"3786_CR52","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1161\/CIRCOUTCOMES.113.000192","volume":"6","author":"M Zalesak","year":"2013","unstructured":"Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y et al (2013) Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 6(5):567\u2013574","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"3786_CR53","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/jhh.2015.103","volume":"30","author":"P Patel","year":"2016","unstructured":"Patel P, Gupta PK, White CM, Stanley AG, Williams B, Tomaszewski M (2016) Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens 30(6):368\u2013373","journal-title":"J Hum Hypertens"},{"issue":"11","key":"3786_CR54","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","volume":"100","author":"M Tomaszewski","year":"2014","unstructured":"Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J et al (2014) High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis. Heart 100(11):855\u2013861","journal-title":"Heart"},{"issue":"17","key":"3786_CR55","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus S, O\u2019Meara E, Desai AS, Claggett B, Lewis EF, Leclair G et al (2017) Spironolactone metabolites in TOPCAT - new insights into regional variation. N Engl J Med 376(17):1690\u20131692","journal-title":"N Engl J Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03786-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03786-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:06:13Z","timestamp":1736413573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03786-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3786"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03786-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is conducted according to the Management Policy of the MHI Hospital Cohort and is approved by the Management Committee of the Biobank as well as the Scientific and Ethics committees of the MHI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients agreed to participate in the Hospital Cohort and signed a consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable (see Ethics approval and Consent to participate).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. de Denus reports grants outside the submitted work from AstraZeneca and RMS\/Dalcor. M.-P. Dub\u00e9 has a minor equity interest in DalCor Pharmaceuticals. J.-C. Tardif has received research grants from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, RegenXBio, and Sanofi; honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, and Pendopharm; and minor equity interest in DalCor Pharmaceuticals. M.-P. Dub\u00e9 and J.-C. Tardif are authors on the following patents without royalties received: \u201cMethods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events,\u201d \u201cGenetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent,\u201d and \u201cMethods for using low dose colchicine after myocardial infarction.\u201d","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}